Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
Phase: N/A
Priority: Normal
Start: 11/05/21
End: 12/05/24
Due: 12/05/25
Phase: N/A
Priority: Normal
Start: 04/17/18
End: 12/31/24
Due: 12/31/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure | NCT05135364 | Yue Han | user2@example.com | None | 2021-11-05 | 2024-12-05 | 2025-12-05 | - | - | 2025-07-14 |
| Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation | NCT03356236 | Yue Han | user2@example.com | None | 2018-04-17 | 2024-12-31 | 2025-12-31 | - | - | 2025-07-14 |